Arix Bioscience plc

Autolus Announces Updated Results From CARPALL Trial

LONDON, February 19, 2019 /PRNewswire/ --

Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, notes that its portfolio company, Autolus Therapeutics plc (NASDAQ: AUTL), has presented updated data from the ongoing Phase 1 CARPALL trial of AUTO1 in a poster presentation at the European Hematology Association 1st European CAR T Cell Meeting held in Paris, France, February 14-16, 2019.  

The announcement can be accessed on Autolus' investor website at https://www.autolus.com/investor-relations and the full text of the announcement from Autolus is contained below.

About Arix Bioscience plc 
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit http://www.arixbioscience.com

Autolus Therapeutics Announces Updated Results From Ongoing CARPALL Trial of Pediatric Acute Lymphoblastic Leukemia Presented at the EHA 1^st European CAR T Cell Meeting in Paris

Updated results confirm AUTO1 data from ASH 2017 

No severe cytokine release syndrome (Grade 3-5) 

86% molecular complete response rate after a single dose of AUTO1  

LONDON, UK, February 19, 2019 -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that Professor Persis Amrolia, Consultant in Bone Marrow Transplant at Great Ormond Street Hospital (GOSH) and NIHR Research Professor of Transplantation Immunology at University College London (UCL) Great Ormond Street Institute of Child Health, presented updated data from the ongoing Phase 1 CARPALL trial of AUTO1 in a poster presentation at the European Hematology Association 1^st European CAR T Cell Meeting held in Paris, France, February 14-16, 2019.